Brahim Achour is an assistant professor at the College of Pharmacy, University of Rhode Island, overseeing research in applied pharmacokinetics, liquid biopsy and precision dosing. Prof. Achour has co-authored more than 50 publications (H-index 20) as well as several patents as co-inventor of a novel liquid biopsy test for model-informed precision dosing. Brahim has extensive experience in multi-‘omics’ as applied to the investigation of drug metabolism and transport. Along with research, Brahim does consultancy work for external and affiliated companies and institutions in relation to the use of systems data in physiologically-based pharmacokinetics and liquid biopsy applications.

Zubida Al-Majdoub is a senior research fellow at the Centre for Applied Pharmacokinetic Research (CAPKR), her research focuses on investigating the expression profiles of drug-metabolizing enzymes, drug transporters and any other interesting proteins in different systems including tissue (liver, kidney, intestine, brain, placenta, skin…etc.) and in vitro systems, for the purpose of enabling in vitro-in vivo extrapolation (IVIVE) and leveraging precision dosing strategies. Another focus of her research in recent years has been related to changes in protein expression in disease state (e.g. Alzheimer’s Disease, dementia, Lewy Bodies and Biliary atresia).

Nasim is currently a postdoc fellow in Stanford University (USA) at Department of Genetics. She granted Ph.D. degree in Life Science in Lausanne (Switzerland). Nasim received her bachelor and a master’s degrees in chemistry and analytical chemistry from Iran. On 2012, she joined the MAS program in Toxicology held in Geneva-Lausanne centers in Switzerland and performed her master thesis in the clinical pharmacology service at Geneva University Hospitals. Nasim is a part of several projects mainly as Bioinformatician. Leveraging combined different state-of-the-art "omics" technologies, the aim of her study is to understand dynamic changes of biological complex network in several studies namely, FAP (Familial Adenomatous Polyposis)- The Human Tumor Atlas Network (HTAN), iPOP(Integrated Personal Omics Profiling)-Lipidomics, MoTrPAC (Molecular Transducers of Physical Activity Consortium), MicroSampling, Biology of Depression. Nasim is also leading hPOP (Human Personalized Omics Profiling).

Youssef Daali is a Professor at the Faculty of Medicine of Geneva University and Head of the Laboratory of the Clinical Pharmacology and Toxicology Service at Geneva University Hospitals. Youssef completed his doctorate in Pharmaceutical Sciences at the School of Pharmacy of Geneva University in 2001. He joined the Clinical Pharmacology Service at Geneva University Hospitals in 2002. Prof Daali is also a senior lecturer at School of Pharmacy. The research activities of Prof Daali are related to personalized medicine with specific interest for drug metabolism, pharmacokinetics, pharmacogenetics and PBPK. Youssef also developed several in vitro models for drugs metabolism and transport characterization and drug-drug interaction studies. Prof Daali has an internationally recognized competence in bioanalysis for drugs and metabolites determination using liquid chromatography mass spectrometry. The scientific contribution of Prof Daali has been awarded in several national and international meetings. He is also member of several national and international societies in the field of pharmacology, bioanalysis and toxicology. He published more than 130 papers in the most important peer-reviewed journals of clinical pharmacology and bioanalysis and has an index H higher than 33.

Prof CB Eap is the head of the Unit of Pharmacogenetics and Clinical Psychopharmacology and the chief of service at the Center for Psychiatric Neurosciences, Department of Psychiatry, Lausanne University Hospital. He is associate professor on the Faculty of Biology and Medicine at the University of Lausanne and lecturer at the School of Pharmaceutical Sciences, University of Geneva. He divides his time among both clinical and research activities. His main field of research is therapeutic drug monitoring and pharmacogenetics / pharmacogenomics, in particular the variability in metabolism of psychotropic drugs (e.g., fast or slow metabolizers for cytochrome P450 isoforms). He has been conducting a large ongoing clinical study (PsyMetab) investigating the environmental, clinical, and genetic influences on metabolic effects induced by psychotropic drugs. He is the main author or coauthor of over 260 publications in peer-reviewed journals. His H-index is 53.

Jean-Luc Reny, MD, PhD. Head of the service of General Internal Medicine at the HUG and Full Professor of Medicine at the Faculty of Medicine in Geneva

Jean-Luc Reny first trained in biochemistry in France and the United States, before undertaking medical studies, specializing in internal medicine and angiology in Paris. At the same time, he continued his scientific work in the field of atherothrombosis. In 2009, he joined the Department of General Internal Medicine at the HUG, where he co-directs the "Geneva Platelet Group", a translational research group working on platelet function and antithrombotic drugs, with several national and international collaborations.

He is strongly involved in pre- and post-graduate teaching, and also has a clinical research activity, focusing in particular on clinical decision strategies in relation to internal medicine patients. He is also involved in several hospital projects, different commissions and the Swiss Society of General Internal Medicine. He leads an enthusiastic team with various cutting-edge competences that make Internal Medicine rich for patients, research and teaching.

Vı́ctor González-Ruiz is a pharmacist (2008) and holds a M.S. in Pharmaceutical R&D (2009). He got a Ph.D. in Analytical Chemistry (2014) from the Complutense University of Madrid, developing LC- and fluorescence-based analytical techniques to study antitumor drugs and their mechanisms of action. In 2015 he joined the Analytical Sciences lab at the School of Pharmaceutical Sciences, University of Geneva, where he currently works as a research associate. His main research interest is the development of toxicology-oriented analytical methodologies (mainly based on CE-MS and LC-MS) and data handling strategies for metabolomics, in collaboration with the Swiss Center for Applied Human Toxicology.

Flavia Storelli is a postdoctoral scholar in the Department of Pharmaceutics of the University of Washington and the lead scientist of the University of Washington Research Affiliate Program on Transporters (UWRAPT, PI: Jashvant Unadkat). Her current research focuses on in vitro in vivo extrapolation of transported-mediated drug disposition (clearance, tissue concentrations) using targeted proteomics.

Before that, she completed a PhD in Pharmaceutical Sciences in the Division of Clinical Pharmacology and Toxicology of Geneva University Hospitals (2014-2018, PIs: Youssef Daali and Jules Desmeules). There, her research focused on CYP-mediated gene-drug-drug-disease interactions in the context of precision medicine, and more particularly on the impact of genetic polymorphisms on the magnitude of drug-drug interactions involving CYP2D6.

Dr. Uppugunduri holds a PhD in Pharmacogenetics/Medical Pharmacology and is currently working as a Senior Researcher & Head of experimental research, at CANSEARCH Research platform in pediatric oncology and hematology. He completed PhD at Department of Pharmacology, JIPMER, Puducherry in 2010. He started working with Prof. Marc Ansari as a post-doctoral fellow at University of Geneva in close collaboration with Clinical Pharmacology division, HUG, Geneva. 

His research focuses on pharmacogenetics and personalized medicine with particular contributions in elucidating drug responses in reaction to cytochrome P450 enzyme genetic variants. He is part of the team headed by Prof. Marc Ansari that works on personalizing chemotherapy and the conditioning regimens prior to stem-cell transplantation in children and adolescents. He founded the forum on personalized medicine on nature network in 2010 (currently available at www.personalizedmedicine.in). He is a member of a number of national and international pharmacological and pharmacogenomic organizations including Clinical Pharmacogenomics Implementation Consortium (CPIC) and Pharmacogenomics Research Network (PGRN). As a member of CPIC, he is currently part of the committee for development of pharmacogenetics guided dosing for few drug-gene pairs. Alongside the research work, he is also undertaking teaching activities especially at University of Geneva, under education division & Global dissemination committees of PGRN.